Literature DB >> 12560242

Global down-regulation of HOX gene expression in PML-RARalpha + acute promyelocytic leukemia identified by small-array real-time PCR.

Alexander Thompson1, Michael F Quinn, David Grimwade, Claire M O'Neill, Momin R Ahmed, Sean Grimes, Mary Frances McMullin, Finbarr Cotter, Terence R J Lappin.   

Abstract

Acute promyelocytic leukemia (APL) is associated with a reciprocal and balanced translocation involving the retinoic acid receptor-alpha (RARalpha). All-trans retinoic acid (ATRA) is used to treat APL and is a potent morphogen that regulates HOX gene expression in embryogenesis and organogenesis. HOX genes are also involved in hematopoiesis and leukemogenesis. Thirty-nine mammalian HOX genes have been identified and classified into 13 paralogous groups clustered on 4 chromosomes. They encode a complex network of transcription regulatory proteins whose precise targets remain poorly understood. The overall function of the network appears to be dictated by gene dosage. To investigate the mechanisms involved in HOX gene regulation in hematopoiesis and leukemogenesis by precise measurement of individual HOX genes, a small-array real-time HOX (SMART-HOX) quantitative polymerase chain reaction (PCR) platform was designed and validated. Application of SMART-HOX to 16 APL bone marrow samples revealed a global down-regulation of 26 HOX genes compared with normal controls. HOX gene expression was also altered during differentiation induced by ATRA in the PML-RARalpha(+) NB4 cell line. PML-RARalpha fusion proteins have been reported to act as part of a repressor complex during myeloid cell differentiation, and a model linking HOX gene expression to this PML-RARalpha repressor complex is now proposed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12560242     DOI: 10.1182/blood.V101.4.1558

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Authors:  Jolanta Grembecka; Shihan He; Aibin Shi; Trupta Purohit; Andrew G Muntean; Roderick J Sorenson; Hollis D Showalter; Marcelo J Murai; Amalia M Belcher; Thomas Hartley; Jay L Hess; Tomasz Cierpicki
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

2.  Analysis of HSC activity and compensatory Hox gene expression profile in Hoxb cluster mutant fetal liver cells.

Authors:  Janet Bijl; Alexander Thompson; Ramiro Ramirez-Solis; Jana Krosl; David G Grier; H Jeffrey Lawrence; Guy Sauvageau
Journal:  Blood       Date:  2005-12-08       Impact factor: 22.113

3.  HOXA4 provides stronger engraftment potential to short-term repopulating cells than HOXB4.

Authors:  Marilaine Fournier; Charles-Étienne Lebert-Ghali; Janetta J Bijl
Journal:  Stem Cells Dev       Date:  2015-08-12       Impact factor: 3.272

4.  High incidence of proviral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell leukemia.

Authors:  Janet Bijl; Martin Sauvageau; Alexander Thompson; Guy Sauvageau
Journal:  Genes Dev       Date:  2005-01-15       Impact factor: 11.361

5.  Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.

Authors:  Katerina Rejlova; Alena Musilova; Karolina Skvarova Kramarzova; Marketa Zaliova; Karel Fiser; Meritxell Alberich-Jorda; Jan Trka; Julia Starkova
Journal:  Epigenetics       Date:  2018-02-07       Impact factor: 4.528

6.  Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.

Authors:  Carla S Wilson; George S Davidson; Shawn B Martin; Erik Andries; Jeffrey Potter; Richard Harvey; Kerem Ar; Yuexian Xu; Kenneth J Kopecky; Donna P Ankerst; Holly Gundacker; Marilyn L Slovak; Monica Mosquera-Caro; I-Ming Chen; Derek L Stirewalt; Maurice Murphy; Frederick A Schultz; Huining Kang; Xuefei Wang; Jerald P Radich; Frederick R Appelbaum; Susan R Atlas; John Godwin; Cheryl L Willman
Journal:  Blood       Date:  2006-04-04       Impact factor: 22.113

7.  A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster.

Authors:  Xueqing Zhang; Zheng Lian; Carolyn Padden; Mark B Gerstein; Joel Rozowsky; Michael Snyder; Thomas R Gingeras; Philipp Kapranov; Sherman M Weissman; Peter E Newburger
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

8.  HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy.

Authors:  Glenda J Dickson; Fabio G Liberante; Laura M Kettyle; Kathleen A O'Hagan; Damian P J Finnegan; Lars Bullinger; Dirk Geerts; Mary Frances McMullin; Terry R J Lappin; Ken I Mills; Alexander Thompson
Journal:  Haematologica       Date:  2013-03-28       Impact factor: 9.941

9.  Thrombopoietin, flt3-ligand and c-kit-ligand modulate HOX gene expression in expanding cord blood CD133 cells.

Authors:  C P McGuckin; N Forraz; R Pettengell; A Thompson
Journal:  Cell Prolif       Date:  2004-08       Impact factor: 6.831

10.  Integrative meta-analysis of differential gene expression in acute myeloid leukemia.

Authors:  Brady G Miller; John A Stamatoyannopoulos
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.